2022 was an important year for triglyceride-related research, with extensive clinical and preclinical data presented at international congresses and published in leading journals. When we asked Editorial Advisory Board members for their highlights, they agreed that the PROMINENT trial of triglyceride (TG) lowering to reduce cardiovascular (CV) risk, published in November 2022, was a major milestone.
New APOC3 loss-of-function data support apoCIII as a treatment target for CV disease prevention
Newly published data on the postprandial kinetics of apoB48 and B100 in chylomicrons, VLDL1, VLDL2, IDL and LDL, in people heterozygous for a loss-of-function (LOF) mutation in the APOC3 gene, indicate the potential benefits of apoCIII lowering for cardiovascular disease (CVD) prevention.
Cholesterol crystals: the next target for intervention in atherosclerotic cardiovascular disease?
Professor John Chapman (Pitié-Salpetrière University Hospital, INSERM, Paris France) discusses the crucial role of cholesterol crystals in atherothrombosis and the evidence suggesting that ethyl eicosapentaenoic acid may modify crystal formation and deposition, with implications for therapeutic intervention in atherosclerotic cardiovascular disease (ASCVD).
Triglyceride-rich lipoproteins and their remnants: Commentary on the 2021 EAS Consensus Statement
The recently published European Atherosclerosis Society (EAS) consensus statement on triglyceride-rich lipoproteins (TRLs) and their remnants provides a critical appraisal of current understanding of the structure, function, and metabolism of TRLs, and their pathophysiological role in atherosclerotic cardiovascular disease (ASCVD).1
Professor Gary Lewis, Director of the Banting and Best Diabetes Centre at the University of Toronto, Canada, and co-author of this important EAS publication, discusses the evidence and its implications for clinicians and patients.
ASCVD risk with persistent hypertriglyceridaemia: What is the latest guidance from ACC?
The ink was barely dry on the 2018 American Heart Association (AHA) and American College of Cardiology (ACC) cholesterol management guidelines1 when new evidence from the REDUCE-IT trial supported a possible role for icosapent ethyl in reducing cardiovascular risk in patients with persistent hypertriglyceridaemia despite the use of statins.2 As a result, the ACC has produced further guidance on the management of patients with persistent hypertriglyceridemia,3 as Dr Michael Miller, Professor of Cardiovascular Medicine at the University of Maryland, Baltimore, USA, and co-author of the publication explains.
